Outcomes in pregnancies with a confined placental mosaicism and implications for prenatal screening using cell-free DNA

被引:75
|
作者
Grati, Francesca Romana [1 ]
Ferreira, Jose [2 ,3 ,4 ]
Benn, Peter [5 ]
Izzi, Claudia [6 ]
Verdi, Federica [7 ]
Vercellotti, Elena [8 ]
Dalpiaz, Cristina [9 ]
D'Ajello, Patrizia [8 ]
Filippi, Elisa [10 ]
Volpe, Nicola [11 ]
Malvestiti, Francesca [1 ]
Maggi, Federico [1 ]
Simoni, Giuseppe [1 ]
Frusca, Tiziana [11 ]
Cirelli, Gaetana [12 ]
Bracalente, Gabriella [10 ]
Lo Re, Antonino [9 ]
Surico, Daniela [8 ]
Ghi, Tullio [11 ]
Prefumo, Federico [6 ]
机构
[1] Impact Lab Grp, Unit Res & Dev, Cytogenet & Med Genet TOMA, Adv Biomed Assays, Busto Arsizio, Varese, Italy
[2] Eduardo Mondlane Univ, Fac Med, Maputo, Mozambique
[3] Maputo Cent Hosp, Dept Obstet & Gynecol, Maputo, Mozambique
[4] Genomed SA, Warsaw, Poland
[5] Univ Connecticut, Ctr Hlth, Dept Genet & Genome Sci, Farmington, CT USA
[6] Azienda Osped Spedali Civili, UO Diag Prenatale, Brescia, Italy
[7] Osped Bolzano, Ostetricia & Ginecol, Bolzano, Italy
[8] Univ Piemonte Orientale, Novara, Italy
[9] Clin Pederzoli, UO Ostetricia & Ginecol, Peschiera Del Garda, Italy
[10] Osped Ca Foncello Treviso, UOC Ginecol & Ostetricia, Treviso, Italy
[11] Univ Parma, Dept Med & Surg, Unit Surg Sci Obstet & Gynecol, Parma, Italy
[12] Osped Santorso AULSS7 Pedemontana VI, Ostetricia & Ginecol, Santorso, Italy
关键词
rare autosomal trisomies; confined placental mosaicism; low birthweight; pregnancy complications; genome-wide cfDNA test; INTRAUTERINE GROWTH-RETARDATION; CHROMOSOMAL MOSAICISM; HEAD CIRCUMFERENCE; UNIPARENTAL DISOMY; FETAL-GROWTH; FOLLOW-UP; DIAGNOSIS; WEIGHT; RISK; CVS;
D O I
10.1038/s41436-019-0630-y
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Purpose To assess the association between confined placental mosaicism (CPM) and adverse pregnancy outcome. Methods A retrospective cohort study was carried out evaluating the outcome of pregnancies with and without CPM involving a rare autosomal trisomy (RAT) or tetraploidy. Birthweight, gestational age at delivery, fetal growth restriction (FGR), Apgar score, neonatal intensive care admission, preterm delivery, and hypertensive disorders of pregnancy were considered. Results Overall 181 pregnancies with CPM and 757 controls were recruited. Outcome information was available for 69% of cases (n = 124) and 62% of controls (n = 468). CPM involving trisomy 16 (T16) was associated with increased incidence of birthweight <3rd centile (P = 0.007, odds ratio [OR] = 11.2, 95% confidence interval [CI] = 2.7-47.1) and preterm delivery (P = 0.029, OR = 10.2, 95% CI = 1.9-54.7). For the other RATs, an association with prenatally diagnosed FGR was not supported by birthweight data and there were no other strong associations with adverse outcomes. Conclusion Excluding T16, the incidence of adverse pregnancy outcomes for pregnancies carrying a CPM is low. RATs can also be identified through genome-wide cell-free DNA screening. Because most of these will be attributable to CPMs, we conclude that this screening is of minimal benefit.
引用
收藏
页码:309 / 316
页数:8
相关论文
共 50 条
  • [31] Prenatal aneuploidy screening using cell free DNA
    Oepkes, Dick
    Tabor, Ann
    Yaron, Yuval
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2015, 213 (04) : 596 - 597
  • [32] Noninvasive prenatal testing for aneuploidy using cell-free DNA - New implications for maternal health
    Hui, Lisa
    OBSTETRIC MEDICINE, 2016, 9 (04) : 148 - 152
  • [33] Implications of fetoplacental mosaicism on cell-free DNA testing: a review of a common biological phenomenon
    Grati, F. R.
    ULTRASOUND IN OBSTETRICS & GYNECOLOGY, 2016, 48 (04) : 415 - 423
  • [34] Cell-free DNA Methylation and Transcriptomic Signature Prediction of Pregnancies with Adverse Outcomes
    Del Vecchio, Giorgia
    Li, Qingjiao
    Li, Wenyuan
    Thamotharan, Shanthie
    Tosevska, Anela
    Morselli, Marco
    Sung, Kyunghyun
    Janzen, Carla
    Zhou, Xianghong
    Pellegrini, Matteo
    Devaskar, Sherin U.
    EPIGENETICS, 2021, 16 (06) : 642 - 661
  • [35] Performance of a cell-free DNA prenatal screening test, choice of prenatal procedure, and chromosome conditions identified during pregnancy after low-risk cell-free DNA screening
    Scarff, Katrina L. L.
    Flowers, Nicola
    Love, Clare J. J.
    Archibald, Alison D. D.
    Hunt, Clare E. E.
    Giouzeppos, Olivia
    Elliott, Justine
    Delatycki, Martin B. B.
    Pertile, Mark D. D.
    PRENATAL DIAGNOSIS, 2023, 43 (02) : 213 - 225
  • [36] Simulated confined placental mosaicism proportion (SCPMP) based on cell-free fetal DNA fraction enrichment can reduce false-positive results in non-invasive prenatal testing
    Zhou, Junhua
    Ouyang, Guojun
    Wu, Long
    Zhang, Min
    Weng, Rongtao
    Lin, Shuman
    Wang, Yuanli
    Li, Kun
    Yang, Xu
    Wu, Yingsong
    Liang, Zhikun
    Li, Fenxia
    Qu, Shoufang
    Yang, Xuexi
    PRENATAL DIAGNOSIS, 2022, 42 (08) : 1008 - 1014
  • [37] Use of Cell-Free Fetal DNA in Maternal Plasma for Noninvasive Prenatal Screening
    Wagner, Amy J.
    Mitchell, Michael E.
    Tomita-Mitchell, Aoy
    CLINICS IN PERINATOLOGY, 2014, 41 (04) : 957 - +
  • [38] Assessment of a Simplified Cell-Free DNA Method for Prenatal Down Syndrome Screening
    Palomaki, Glenn E.
    Eklund, Elizabeth E.
    Kloza, Edward M.
    Lambert-Messerlian, Geralyn M.
    CLINICAL CHEMISTRY, 2022, 68 (11) : 1449 - 1458
  • [39] Patient experiences with prenatal cell-free DNA screening in a safety net setting
    Riggan, Kirsten A.
    Barwise, Amelia
    Yap, Jane Q.
    Condon, Niamh
    Allyse, Megan A.
    PRENATAL DIAGNOSIS, 2024, 44 (04) : 409 - 417
  • [40] Test failure in prenatal cell-free DNA aneuploidy screening: nonreportable, but not nonsignificant
    Pan, Min
    Li, Yang-Yue
    Li, Dong-Zhi
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2023, 229 (04) : 474 - 475